Hovione and Solvias have announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals.
This strengthens Hovione’s expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias’ excellence in solid state chemistry.
Hovione offers a series of innovative particle engineering technologies focused on amorphous solid dispersions, crystal design and reduction and control of particle size.
The collaboration provides Hovione access to Solvias’ co-crystallization expertise and capabilities, thus reinforcing and complementing the crystal design solutions to overcome poor bioavailability and other drug delivery challenges.
Solvias continues its strategy of partnering to enhance access to its solid-state solutions.
“We are delighted to announce this collaboration with Solvias increasing the breadth of drug delivery solutions through our Particle Design offering. Solvias has a tremendous reputation for science, quality and expertise in crystal design for improved drug performance. This agreement reinforces our strategy of combining strengths with innovative companies to allow our customers a seamless and integrated approach to their drug delivery challenges.” said Dr. Colin Minchom, Hovione’s Vice President of Particle Design.
Dr. Martina Diekmann, Solvias’ Global Head of Business Development Analytics commented “Solvias is delighted to work with Hovione. In establishing this agreement with Hovione, we are able to generate added value for our customers and to help them solving their drug delivery requirements.”